摘要
目的通过相关回顾性病例收集研究,探究使用酪酸梭菌肠球菌三联活菌片是否具有提高晚期非小细胞肺癌(NSCLC)患者吉西他滨联合铂类(GP)化疗方案的疗效,减轻化疗带来的毒副作用。方法调取2014年1月至2018年7月在福州某三甲医院肿瘤科接受GP化疗方案治疗的晚期NSCLC患者的医疗记录,纳入78例患者的相关数据,采用SPSS 25.0软件进行数据统计分析。结果与对照组相比,使用酪酸梭菌肠球菌三联活菌片对患者的疾病控制率、无进展生存时间的影响具有显著性差异(P值分别为0.048、0.012),对疾病缓解率和不良反应风险的影响均无显著性差异(P>0.05)。结论在晚期NSCLC患者中,GP化疗方案治疗联合使用酪酸梭菌肠球菌三联活菌片可能提高患者的疗效。
Objective To explore the effect of clostridium butyricum enterococcus triple viable tablet on the efficacy and adverse reactions of gemcitabine plus platinum(GP) regimen for the patients with advanced non-small cell lung cancer(NSCLC).Methods The records of 78 NSCLC patients who treated with GP regimen as first-line palliative chemotherapy were reviewed,and the related data were recorded.Statistical analyses were performed with SPSS 25.0.Results Compared with the control group,the probiotic preparation group showed a significant difference in disease control rate and progression-free survival(P value are 0.048 and 0.012 respectively),while there were no significant differences in objective response rate and the risk of adverse reaction events(P>0.05).Conclusion The clostridium butyricum enterococcus triple viable tablet might improve the efficacy of GP regimen as a first-line palliative chemotherapy for advanced NSCLC patients.
作者
林莉莉
张妍
刘志宏
吴珏
宋洪涛
LIN Lili;ZHANG Yan;LIU Zhihong;WU Jue;SONG Hongtao(Department of Pharmacy,No.900 Hospital of Joint Logistics Units,Fuzhou 350025,China;Department of Oncology,No.900 Hospital of Joint Logistics Units,Fuzhou 350025,China)
出处
《药学实践杂志》
CAS
2019年第3期268-273,共6页
Journal of Pharmaceutical Practice
基金
福州总医院杰出青年培育项目(2016Q05)
